Collection and assembly of data: Marian Wiseman
Data analysis and interpretation: Dean H. Gesme, Marian Wiseman
Manuscript writing: Dean H. Gesme, Marian Wiseman
Final approval of manuscript: Dean H. Gesme, Marian Wiseman

Corresponding author: Marian Wiseman, MA, Wiseman Communications, 213 8th St NE, Washington, DC 20002; e-mail: marian.wiseman@earthlink.net.

DOI: 10.1200/JOP.2010.000214

Reference

1. Dubinsky I, Jennings K, Greengarten M, et al: 360-degree physician performance assessment. *Healthc Q* 13:71-76, 2010

ERRATUM ERRATUM **ERRATUM** ERRATUM ERRATUM

The September 2010 article by Towle and Barr, entitled, “National Practice Benchmark: 2010 Report on 2009 Data” (*J Oncol Pract* 6:228-231, 2010), contained errors.

In the Results section, under Level 1 Quantitative Benchmarks, the fourth and fifth paragraphs referred to total revenue and total practice expense, whereas it should have been total medical revenue and total operating expense, respectively, as follows:

“Total **medical revenue** and total **operating expense** are among the most important data that oncology practices monitor on a regular basis. Figure 5 shows 3-year trends for these important metrics as well as the COGPF. Total **medical revenue** is defined as all **revenue** collected **in the period** for the **provision of medical goods and services**. **This does not include nonmedical revenue, which is defined as revenue earned for services other than the provision of medical care.** Total **operating expense** is defined as all cash expenses for the period **except for W-2 physician compensation**. COGPF is defined as the total of all money paid for drugs in the period less rebates or other cash reductions received in the same period. Each of these data elements is reported as the average per FTE HemOnc.”

“It is interesting to note that total **medical revenue** and total **operating expense** **track one another through the three years, but the cost of goods paid for increases in each year. The decrease in total operating expense that we see between 2008 and 2009 was achieved even with a continued rise in drug costs.** We believe this indicates an overall lowering of the cost of practice operations even as the cost of drugs continues to rise, consistent with the slight increase in the number of new patients per FTE HemOnc. These three measures indicate an overall increase in service delivery efficiency.”

In Figure 5, data were given for total revenue and total practice expense, whereas data should have been given for total medical revenue and total operating expense. In addition, incorrect data were given for the cost of goods paid for (COGPF). The corrected figure is reprinted below in its entirety.

Figure 5. Three-year trend in total **medical revenue**, total **operating expense**, and cost of goods paid for (COGPF). Percentages represent change from one year to the next.

The online version has been corrected in departure from the print. The authors apologize to the readers for the mistakes.

DOI: 10.1200/JOP.2011.000270